Giving China access to Nvidia's best chips will help slow down Chinese AI progress: Dan Niles
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
19 minutes ago
- Yahoo
Leerink Partners Reiterates a Buy Rating on PROCEPT BioRobotics (PRCT)
PROCEPT BioRobotics Corporation (NASDAQ:PRCT) is one of the . On August 8, Leerink Partners analyst Mike Kratky reiterated a Buy rating on PROCEPT BioRobotics Corporation (NASDAQ:PRCT), keeping the associated price target at $83. A medical technician using surgical robotics to perform minimally-invasive urologic surgery in an operating room. He based the optimistic rating on the stability and growth of PROCEPT BioRobotics Corporation's (NASDAQ:PRCT) performance, stating that the company reported a 4% sales beat in Q2. This growth was attributed to strong international momentum and higher average selling prices in the US. The analyst added that the company's full-year sales guidance was raised slightly despite a softer Q3, and the gross margin guidance was improved as well. This suggests a positive outlook for the rest of the year, according to the analyst. PROCEPT BioRobotics Corporation (NASDAQ:PRCT) is a commercial-stage surgical robotics company that develops transformative solutions for urology. The company manufactures and sells the AquaBeam Robotic System, which is an image-guided, surgical robotic system used in minimally invasive urologic surgery. While we acknowledge the potential of PRCT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
Yahoo
19 minutes ago
- Yahoo
AleraCare and PURE Healthcare Announce Intent to Merge
The combined company will create a leading ambulatory infusion platform with more than 75 outpatient locations across 14 states throughout the U.S. PHOENIX & TAYLORSVILLE, Utah, August 13, 2025--(BUSINESS WIRE)--AleraCare, a leading provider of infusion and specialty pharmacy services across the U.S., and PURE Healthcare, a leading national medical group that delivers healthcare services for individuals with complex chronic conditions such as rheumatoid arthritis, Crohn's disease, multiple sclerosis, Alzheimer's disease and other autoimmune conditions, today announced that the businesses have entered into a definitive merger agreement. Terms of the transaction were not disclosed. The proposed merger creates an unprecedented opportunity to provide high-quality patient care, improve clinical outcomes and enhance the availability of infusion services that lower the overall cost to the healthcare system overall. Founded in 2019, AleraCare's core lines of business include ambulatory infusion centers, home infusion therapy and specialty pharmacy. Administered at convenient, accessible, patient-first locations, AleraCare is focused on maintaining trusted-partner status with physicians, payors, drug distributors and pharmaceutical manufacturers. The company has rapidly expanded to over 30 ambulatory infusion centers across the country and is a provider-of-choice for infusion services to high-need and medically complex populations. Pure Healthcare, founded in 2018, is on a mission to transform the healthcare industry by making infusion therapy more affordable and accessible—while delivering a personalized, patient-centered experience. Pure specializes in treating chronic and autoimmune conditions such as Alzheimer's disease, multiple sclerosis, and rheumatoid arthritis, offering innovative, high-quality care tailored to individual needs. Its flagship offering, Pure Infusion Suites, has expanded to 43 locations across 14 states. These state-of-the-art suites prioritize patient comfort with private rooms, snacks, and entertainment, all while significantly lowering the cost of infusion services. Pure Healthcare also alleviates the administrative burden for referring providers by supporting patient authorizations and fostering strong partnerships with insurers, ensuring a seamless and efficient care journey from referral to treatment. The transaction is expected to close in the fourth quarter of 2025, and remains subject to customary closing conditions, including the expiration or termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976. Holland & Knight is serving as legal counsel for AleraCare. Kunzler Bean & Adamson is serving as legal counsel and Cantor Fitzgerald is acting as financial advisor for PURE Healthcare. About AleraCare AleraCare is a leading provider of infusion treatments and pharmacy services for high-need and medically complex populations. The company's core lines of business include ambulatory infusion centers, home infusion therapy and specialty pharmacy. AleraCare provides care to patients in over 30 locations across six states throughout the U.S., including Arizona, California, Colorado, Idaho, New Mexico and Utah. For more information, please visit About PURE Healthcare Pure Healthcare, founded by BUILD Capital Partners in 2018, is a national medical group dedicated to reducing healthcare costs and improving outcomes for patients with complex chronic and autoimmune conditions like rheumatoid arthritis, Crohn's disease, multiple sclerosis, and Alzheimer's. As a market leader in infusion therapy, Pure Healthcare operates Pure Infusion Suites alongside specialty clinics in rheumatology and neurology, including Memory Treatment Centers and Montana Arthritis Centers. Through strategic payer partnerships, streamlined patient authorizations, and a commitment to personalized, high-quality care, Pure Healthcare delivers scalable value to patients, providers, and payers nationwide. Learn more at View source version on Contacts Media Contacts:AleraCare Mike GellerProfile Advisorsmgeller@ Pure Healthcare Andy Sortormarketing@
Yahoo
19 minutes ago
- Yahoo
Top Stock Movers Now: Lennar, Gildan Activewear, CAVA Group, and More
Key Takeaways U.S. equities edged higher at midday, with the S&P 500 and Nasdaq adding to their record closes, on optimism the Federal Reserve will lower interest rates next month. The hope of falling borrowing costs lifted shares of Lennar and rival home builders. CAVA Group's same-store sales came in well below expectations, sending shares of the Mediterranean-themed restaurant lower.U.S. equities edged higher at midday on continuing optimism the latest consumer inflation data will open the door to the Federal Reserve to cut interest rates next month. The S&P 500 and Nasdaq added to their record closes yesterday, and the Dow Jones Industrial Average was higher as well. Speculation that the Fed may make a large reduction in borrowing costs sent the 10-year Treasury yield lower and lifted shares of home builders Lennar (LEN), D.H. Horton (DHI), and PulteGroup (PHM). Shares of Gildan Activewear (GIL) jumped when the T-shirt manufacturer agreed to purchase undergarment maker Hanesbrands (HBI) for $2.2 billion, less than what was reported earlier. Hanesbrands shares gained as well. V2X (VVX) shares advanced on an upgrade from Bank of America, which said it was optimistic about the defense contractor's growth. CAVA Group (CAVA) shares tumbled when the Mediterranean-themed restaurant chain reported weaker-than-anticipated same-restaurant sales and reduced its guidance as consumers pulled back spending at its locations. Shares of CoreWeave (CRWV) tumbled after the provider of artificial intelligence computing posted a much larger-than-expected loss as expenses soared, and it warned it would continue to face higher costs to keep up with demand for its products. Circle Internet Group (CRCL) shares slid when the distributor of the USDC stablecoin announced a sale of 10 million Class A shares that includes 2 million from the company and 8 million from investors. Oil futures declined. Gold prices rose. The U.S. dollar lost ground to the euro, pound, and yen. Major cryptocurrencies were mixed. Read the original article on Investopedia Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
